The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis

Adhya, Zoe; Borozdenkova, Svetlana; Karim, Mohammed Yousuf

doi:10.1093/ndt/gfq860

Cited by 47 publications

(36 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, leukocyte chemotactic factors and their receptors are over-expressed in NR kidneys. CCL19 codes for macrophage-inflammatory protein beta-3, a T, B and dendritic cell chemoattractant previously shown to be expressed in SLE (15, 16). Transcripts for the B cell chemoattractant CXCL13, which is selective for B cells and follicular T cells were upregulated.…”

Section: Discussionmentioning

confidence: 99%

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment

Parikh

Malvar

Song

et al. 2017

Translational Research

View full text Add to dashboard Cite

The consequences of treatment for the kidney at the molecular level have not been explored in human lupus nephritis (LN). In this investigation, changes in intra-renal transcript expression were measured and correlated with response in a LN cohort that underwent serial kidney biopsies. The intra-renal transcript expression of 19 patients with proliferative LN (Class III or IV) was measured at diagnostic biopsy (Bx1) and after induction therapy was completed (Bx2) using Nanostring® technology. Patients were segregated by clinical response into complete responders (n=5, CR) or nonresponders (n=4, NR). Transcript expression for each biopsy was compared to normal controls (n=4) and the change in expression was compared in each responder group and between groups. Compared to controls, the CR group had 21 and 28 while NR had 45 and 103 differentially-expressed transcripts at Bx1 and Bx2, respectively. The profiles of these differentially-expressed genes indicated that the type I and II interferon, alternative complement and T cell signaling pathways discriminated CR from NR. Comparing the change in transcript expression from Bx1 to Bx2 revealed a 5-gene signature that differentiated NR from CR and included increased IL1RAP and FCAR in NR and increased NCAM1 in CR. In summary, molecular imaging of serial kidney biopsies from LN patients shows several immune and inflammatory pathways that are dysregulated in the kidneys during active disease that may serve as therapeutic targets to improve clinical response. This approach to LN biomarker development may facilitate personalized medicine in LN and improve long-term kidney outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment

Parikh

Malvar

Song

et al. 2017

Translational Research

View full text Add to dashboard Cite

show abstract

“…Current efforts are focused on identification of more sensitive and specific biomarkers to diagnose and monitor renal disease in both adult and pediatric patients with SLE, with the hope to optimize synchronization of treatment with active disease, distinguish active inflammation from irreversible damage, and to facilitate development of new therapeutics through clinical trials [Adhya et al 2011;Mok, 2010;Rovin and Zhang, 2009] (Table 4).…”

Section: Other Potential T-cell-based Biomarkers Previous Studies Hamentioning

confidence: 99%

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Liu

Kao

Manzi

et al. 2013

Therapeutic Advances in Musculoskeletal

106

View full text Add to dashboard Cite

Abstract:The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.

show abstract

“…As the knowledge of cytokine biology is increasing, they are being tested for biomarker potential in various diseases. Availability of more sophisticated techniques, such as multiplex bead assays, has helped in simultaneously testing multiple cytokines . A number of cytokines have been identified to have positive correlation with disease activity and it is not possible to discuss all of them.…”

Section: Cytokines and Adhesion Moleculesmentioning

confidence: 99%

“…Virtually every other cytokine has been tested as a biomarker in LN . It is not possible to discuss all of them here.…”

Section: Cytokines and Adhesion Moleculesmentioning

confidence: 99%

Biomarkers in lupus nephritis

Misra

Gupta

2015

Int J of Rheum Dis

View full text Add to dashboard Cite

Lupus nephritis (LN) has significant impact on the outcome of patients with systemic lupus erythematosus (SLE). In the absence of any new breakthrough for management of LN over the last few years, using existing treatment modalities in a more effective manner is the mainstay of improving outcomes. For effectively using the drugs, disease activity needs to be assessed accurately and more objectively, which is not possible with present clinical assessment tools. Biomarkers help in accurate assessment of disease activity and enable the physician to individualize the therapy. Conventional disease activity markers have limitations which need to be addressed and research in the area of biomarker discovery in LN has immensely expanded over the last two decades as evident by the literature. Moreover, biomarkers for LN should be different from the markers of overall disease activity as LN requires significant immunosuppression, unlike other non-renal manifestations of SLE. Newly discovered biomarkers exhibit qualities pertaining to different aspects of disease activity and damage. In this review, we discuss the established as well as new biomarkers of SLE in the light of their role in LN diagnosis, follow-up, prediction of renal flare and correlation with renal histology findings.

show abstract

The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis

Cited by 47 publications

References 47 publications

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Biomarkers in lupus nephritis

Contact Info

Product

Resources

About